With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13991-08-7,1,2-Bis(diphenylphosphino)benzene,as a common compound, the synthetic route is as follows.
Example 7 (EX 7) (0136) IrCl3(THT)3 (150 mg, 0.27 mmol) was placed in a round-bottom flask, (0137) (119 mg, 0.27 mmol), 15 ml decalin, and 15 ml dimethylformamide were subsequently added thereto to obtain the first mixture. The first mixture was heated under reflux and under a nitrogen atmosphere for a period of 6 hours. After the reaction was completed and the temperature was cooled down to room temperature, decalin in the first mixture was removed by reduced pressure distillation. Thereafter, (0138) (51 mg, 0.27 mmol) and 15 ml dimethylformamide were sequentially added to the first mixture, from which decalin was removed, to obtain a second mixture. The second mixture was heated under reflux and under a nitrogen atmosphere for a second reaction period of 12 hours. After the reaction was completed and the temperature was reduced to room temperature, dimethylformamide in the second mixture was removed by reduced pressure distillation to obtain a solid. The solid was washed using diethyl ether to obtain an intermediate product (400 mg, 70% yield).
13991-08-7, The synthetic route of 13991-08-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; National Tsing Hua University; Chi, Yun; Liao, Jia-Ling; US8957208; (2015); B1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate